Skip Navigation

JNCI Journal of the National Cancer Institute 1998 90(18):1327-1329; doi:10.1093/jnci/90.18.1327
© 1998 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by McNeil, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McNeil, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

New Pap Test Technologies Hit Heavy Seas but Sales Keep Flying

If you go by the headlines, it has not been a good year for the new Pap test technologies. In February the long-awaited "TEC report" from the Technical Evaluation Center of the Blue Cross and Blue Shield Association turned thumbs down on all three of the high-tech cervical cancer screening tools now on the market -- a novel slide preparation technique and two automated slide readers.

"Not cost effective" and "minimal advancement" said the headlines. The TEC report had evaluated the technologies in terms of mortality and concluded that they would have little impact on life expectancy for women who were screened regularly, despite their relatively high cost.

Then in July, the American College of Obstetricians and Gynecologists issued an official ACOG Committee Opinion and a press release stating that the same three technologies were "not standard of care." . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?